461030.Kq
The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
Business. The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
The company maintains a strong liquidity position, with a current ratio of 15.37, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to KRW 2,081,621,720, which is a substantial portion of its total assets of KRW 27,119,871,680. The price-to-book ratio of 2.96 suggests that the market values the company at nearly three times its book value, reflecting investor confidence in its intangible assets and future earnings potential.
Profitability metrics reveal a challenging financial position. The company reported a net loss of KRW 7,933,872,390 and an operating loss of KRW 8,664,254,150, resulting in a negative return on equity of -31.53% and a negative return on assets of -29.25%. These figures are significantly below the industry median for profitability, indicating that the company is underperforming relative to its peers in terms of generating returns on equity and assets.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, particularly in its primary operating region.
Looking ahead, the company is projected to continue experiencing a decline in revenue, with a negative growth trajectory expected in the current fiscal year. The operating cash flow of -KRW 6,202,213,770 and free cash flow of -KRW 7,508,337,410 indicate that the company is not generating sufficient cash from operations to fund its activities, necessitating reliance on external financing or asset sales.
The risk assessment indicates a low probability of dilution and no immediate liquidity concerns, with no filing-based flags detected. However, the company's negative net income and operating income suggest a need for careful monitoring of its capital structure and financial strategy to avoid potential dilution in the future.
Recent filings and transcripts do not indicate any significant events that would alter the company's current financial trajectory. The company's financial performance and strategic direction remain consistent with its recent disclosures, with no material changes in its business operations or financial outlook.
- The company has a strong liquidity position, with a current ratio of 15.37 and significant cash reserves.
- The company is currently unprofitable, with a net loss of KRW 7,933,872,390 and a negative return on equity of -31.53%.
- The company's revenue is concentrated in a single business segment, increasing its exposure to market-specific risks.
- The company is projected to continue experiencing a decline in revenue, with a negative growth trajectory expected in the current fiscal year.
- The company has a low probability of dilution and no immediate liquidity concerns, but its negative net income and operating income suggest a need for careful monitoring of its capital structure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 461030.KQ Market data — financials · 2026-05-26